SE9503495L - Nytt protein - Google Patents

Nytt protein

Info

Publication number
SE9503495L
SE9503495L SE9503495A SE9503495A SE9503495L SE 9503495 L SE9503495 L SE 9503495L SE 9503495 A SE9503495 A SE 9503495A SE 9503495 A SE9503495 A SE 9503495A SE 9503495 L SE9503495 L SE 9503495L
Authority
SE
Sweden
Prior art keywords
gly
asp
protein
ser
trp
Prior art date
Application number
SE9503495A
Other languages
English (en)
Swedish (sv)
Other versions
SE9503495D0 (sv
Inventor
Per Aakesson
Lars Bjoerck
Original Assignee
Actinova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinova Ltd filed Critical Actinova Ltd
Priority to SE9503495A priority Critical patent/SE9503495L/xx
Publication of SE9503495D0 publication Critical patent/SE9503495D0/xx
Priority to AU72332/96A priority patent/AU7233296A/en
Priority to US09/051,380 priority patent/US6576741B1/en
Priority to DE69634206T priority patent/DE69634206D1/de
Priority to PCT/SE1996/001238 priority patent/WO1997013786A1/en
Priority to EP96933703A priority patent/EP0862580B1/de
Publication of SE9503495L publication Critical patent/SE9503495L/xx
Priority to US10/374,535 priority patent/US7361750B2/en
Priority to US11/418,770 priority patent/US7588762B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9503495A 1995-10-09 1995-10-09 Nytt protein SE9503495L (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE9503495A SE9503495L (sv) 1995-10-09 1995-10-09 Nytt protein
AU72332/96A AU7233296A (en) 1995-10-09 1996-10-02 Streptoccal inhibitor of complement-mediated lysis, protein sic
US09/051,380 US6576741B1 (en) 1995-10-09 1996-10-02 Streptoccal inhibitor of complement-mediated lysis, protein SIC
DE69634206T DE69634206D1 (de) 1995-10-09 1996-10-02 Sic protein von streptococcus, ein inhibitor der komplement-vermittelten lyse
PCT/SE1996/001238 WO1997013786A1 (en) 1995-10-09 1996-10-02 Streptoccal inhibitor of complement-mediated lysis, protein sic
EP96933703A EP0862580B1 (de) 1995-10-09 1996-10-02 Sic protein von streptococcus, ein inhibitor der komplement-vermittelten lyse
US10/374,535 US7361750B2 (en) 1995-10-09 2003-02-26 Streptoccal inhibitor of complement-mediated lysis, protein SIC
US11/418,770 US7588762B2 (en) 1995-10-09 2006-05-05 Streptoccal inhibitor of complement-mediated lysis, protein SIC

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9503495A SE9503495L (sv) 1995-10-09 1995-10-09 Nytt protein

Publications (2)

Publication Number Publication Date
SE9503495D0 SE9503495D0 (sv) 1995-10-09
SE9503495L true SE9503495L (sv) 1997-04-10

Family

ID=20399743

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9503495A SE9503495L (sv) 1995-10-09 1995-10-09 Nytt protein

Country Status (6)

Country Link
US (3) US6576741B1 (de)
EP (1) EP0862580B1 (de)
AU (1) AU7233296A (de)
DE (1) DE69634206D1 (de)
SE (1) SE9503495L (de)
WO (1) WO1997013786A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1905834A3 (de) * 1999-12-23 2008-07-23 Vmax Limited Virulenzgene, Proteine und deren Verwendung
AU2002249342A1 (en) * 2001-03-14 2002-09-24 Cambridge University Technical Services Limited Assays, methods and means for targeting streptococcal inhibitor of complement (sic)
FR2886312B1 (fr) * 2005-05-26 2012-12-14 Abag Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a streptococcus pyogenes
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367890A1 (de) 1988-11-11 1990-05-16 HighTech Receptor AB Protein Arp, mit Bindungsaktivität für Immunglobulin A sowie dessen Klonierung und Expression
JP2871709B2 (ja) * 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
SE9002212D0 (sv) 1990-06-21 1990-06-21 Hightech Receptor Ab Igg binding protein

Also Published As

Publication number Publication date
WO1997013786A1 (en) 1997-04-17
SE9503495D0 (sv) 1995-10-09
US20060205925A1 (en) 2006-09-14
US7361750B2 (en) 2008-04-22
DE69634206D1 (de) 2005-02-24
EP0862580A1 (de) 1998-09-09
EP0862580B1 (de) 2005-01-19
US6576741B1 (en) 2003-06-10
US20040010117A1 (en) 2004-01-15
WO1997013786A9 (en) 2008-09-04
US7588762B2 (en) 2009-09-15
AU7233296A (en) 1997-04-30

Similar Documents

Publication Publication Date Title
Dietzschold et al. Chemical and immunological analysis of the rabies soluble glycoprotein
Carlen et al. Composition of pellicles formed in vivo on tooth surfaces in different parts of the dentition, and in vitro on hydroxyapatite
Rucinski et al. Antiheparin proteins secreted by human platelets. Purification, characterization, and radioimmunoassay
Blombäck et al. Primary Structure of Human Fibrinogen and Fibrin: II. STRUCTURAL STUDIES ON NH2-TERMINAL PART OF γ CHAIN
MX9202724A (es) Composicion que comprende un vector recombinante del agente lelystad y vacuna que comprende la misma.
Spiegelberg et al. Structural studies of human γD myeloma protein
CA2131826A1 (en) MN Gene and Protein
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
UA43310C2 (uk) Поліпептид вірусу гепатиту с корейського типу (khcv), кднк khcv, полінуклеотид, що кодує поліпептид khcv, рекомбінантний експресуючий вектор, клітина, трансформована вектором, поліпептид, який містить епітоп, спосіб одержання поліпептиду, діагностичний засіб для визначення антитіла, спрямованого проти антигену khcv, діагностичний набір, діагностичний спосіб визначення антитіла, спрямованого проти антигену khcv, моноклональне антитіло, клітинна лінія, діагностичний засіб для визначення епітопу khcv у зразку, що піддають тестуванню, спосіб визначення епітопу khcv, вакцина для лікування або профілактики інфекції khcv (варіанти), набір для визначення полінуклеотиду khcv, спосіб визначення полінуклеотиду з khcv
BRPI0011369B8 (pt) método de detecção precoce e kit de diagnóstico precoce de uma infecção flaviviral, processo de purificação da proteína ns1 de um flavivírus,composição imunogênca,utilização da proteína ns1,de pelo menos um anticorpo monoclonal anti-ns1 e da proteína ns1 de forma hexamérica,e, processo de expressão de um polinucleotídeo codificado para a proteína ns1 de um vírus da dengue
NO20025153D0 (no) FremgangsmÕter og sammensetninger for Õ svekke formering av HIV-1
BR122015016384B8 (pt) polipeptídio recombinante ou isolado, molécula de ácido nucléico, kit de diagnóstico para detectar a infecção pelo vírus da hepatite e, composição de vacina, composição farmacêutica, vetor de expressão recombinante, célula hospedeira transformada e uso do polipeptídeo recombinante ou isolado
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
UY24130A1 (es) Peptido p277 analogos, y composiciones farmaceuticas que los comprenden para el tratamiento o diagnostico de diabetes.
Despont et al. Structural studies on a human IgAl myeloma protein with a carboxy-terminal deletion
SE9503495D0 (sv) New protein
Prahl et al. Carboxy-terminal structure of the α chain of human IgA [immunoglobulin A] myeloma proteins
DE69529272D1 (de) MONOKLONALER ANTIKÖRPER GEGEN DAS HUMANE Mx-PROTEIN MxA
Cates et al. C4B deficiency is not associated with meningitis or bacteremia with encapsulated bacteria
JPH0967397A (ja) 抗ｊｃウイルス抗体
FI913714A0 (fi) Peptider med foer a 1-mikroglobulin karakteristiska antigeniska determinanter.
NO903681L (no) Monoklonale antistoffer mot aktiverte ras-proteiner med aminosyremutasjoner i posisjon 13 i proteinet.
Kelly et al. Immunological studies on the major haptenic peptides from performic acid oxidized ferredoxin from Clostridium pasteurianum
Clyne et al. Characterization of staphylococcal λ-lysin
BR9908476A (pt) Peptìdeo, composição terapêutica, e, processo para conferir imunidade protetora a um paciente, contra a infecção de s. pneumoniae

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9503495-5